tiprankstipranks
Trending News
More News >
Apyx Medical Corporation (APYX)
NASDAQ:APYX
Advertisement

Apyx Medical (APYX) AI Stock Analysis

Compare
198 Followers

Top Page

APYX

Apyx Medical

(NASDAQ:APYX)

Select Model
Select Model
Select Model
Neutral 47 (OpenAI - 4o)
Rating:47Neutral
Price Target:
$2.00
▼(-16.32% Downside)
Apyx Medical's overall stock score is primarily impacted by its weak financial performance, characterized by declining revenue and persistent losses. While technical analysis shows some positive trends, the valuation remains unattractive due to a negative P/E ratio and lack of dividend yield. The earnings call provided some optimism with strategic shifts and improved guidance, but financial challenges remain the most significant factor.
Positive Factors
Strategic Leadership Appointments
The appointment of experienced sales leaders is expected to drive growth in domestic and international markets, enhancing the company's market position and sales execution over the long term.
Expansion into China
The launch of Renuvion in China opens access to a large and growing aesthetic market, potentially increasing revenue and market share in a key international region.
AYON System Launch
The successful launch and strong presales of the AYON system indicate robust demand and could drive future revenue growth, reinforcing the company's innovation-driven business model.
Negative Factors
Declining Revenue
The decline in revenue reflects challenges in maintaining sales momentum, which could impact long-term financial stability and necessitate strategic adjustments.
OEM Segment Sales Decline
A significant drop in OEM sales suggests potential issues in product demand or competitive pressures, which could affect future revenue streams and market competitiveness.
Cash Flow Challenges
Persistent negative cash flows indicate liquidity issues, limiting the company's ability to invest in growth opportunities and potentially affecting long-term operational sustainability.

Apyx Medical (APYX) vs. SPDR S&P 500 ETF (SPY)

Apyx Medical Business Overview & Revenue Model

Company DescriptionApyx Medical Corporation, an energy technology company, develops, manufactures, and sells medical devices in the cosmetic and surgical markets worldwide. The company operates in two segments, Advanced Energy and Original Equipment Manufacturing (OEM). It offers Helium Plasma Generator for delivery of RF energy and helium to cut, coagulate and ablate soft tissue during open and laparoscopic surgical procedures. The company offers Renuvion branded products for the cosmetic surgery market that enable plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and J-Plasma branded products for the hospital surgical market. It also develops, manufactures, and sells disposable hand pieces, and OEM generators and accessories. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.
How the Company Makes MoneyApyx Medical generates revenue primarily through the sale of its Renuvion devices and consumables, which are used in various surgical and aesthetic applications. The company has established a recurring revenue model through the sale of disposable components that accompany its devices, contributing significantly to its earnings. Additionally, Apyx Medical engages in strategic partnerships with healthcare providers and distributors to expand its market reach and drive adoption of its technologies. These partnerships often include training and support services that promote the effective use of its products, further enhancing revenue opportunities. The company's focus on innovation and expanding its product portfolio also plays a critical role in attracting new customers and retaining existing ones, thereby strengthening its financial performance.

Apyx Medical Earnings Call Summary

Earnings Call Date:Aug 07, 2025
(Q2-2025)
|
% Change Since: |
Next Earnings Date:Nov 06, 2025
Earnings Call Sentiment Neutral
The earnings call reflected a strategic shift with positive momentum from the AYON system launch and restructuring benefits, countered by revenue declines in OEM and overall sales. The updated revenue guidance indicates optimism for future growth.
Q2-2025 Updates
Positive Updates
Successful Appointment of Senior Sales Leaders
John Featherstone and Simon Davies were appointed as senior sales leaders for North America and Europe/Asia, respectively, bringing extensive experience in the aesthetics industry.
AYON System Pre-Sales Exceed Expectations
Early results from AYON presales have exceeded expectations, leading to an update in revenue targets for 2025.
Cost Reduction and Restructuring Benefits
Significant improvements from cost reduction and restructuring initiatives implemented in November 2024 have resulted in a leaner operating structure and reduced cash burn.
Launch of Renuvion in China
Renuvion launched in China with a distribution agreement with GlamMoon Medical Technology, generating strong interest from surgeons and patients.
Updated Revenue Guidance for 2025
Total revenue guidance increased to $50 million to $52 million from previous guidance of $47.6 million to $49 million, driven by the AYON system launch.
Negative Updates
Revenue Decline in Q2 2025
Total revenue decreased by 6% to $11.4 million compared to $12.1 million in the previous year, primarily due to a decrease in OEM product sales.
OEM Segment Sales Decline
Sales in the OEM segment decreased by 29% compared to the previous year.
Domestic and International Revenue Decrease
Domestic revenue decreased by 11% and international revenue decreased by 4% year-over-year.
Company Guidance
During the second quarter 2025 earnings call, Apyx Medical announced a strategic shift in focus, highlighted by the appointment of two seasoned sales leaders to drive growth in both domestic and international markets. The company reported a total revenue of $11.4 million, down 6% from the previous year, with Advanced Energy products generating $9.7 million. Despite a dip in sales of OEM products and single-use handpieces, Apyx experienced strong presales for its new AYON system, which combines multiple body contouring technologies. The company revised its full-year 2025 revenue guidance upward to $50-52 million, with anticipated Advanced Energy revenue between $42-44 million. Operational efficiency improvements contributed to a reduced net loss of $3.8 million and an adjusted EBITDA loss of $2 million. Apyx also highlighted the positive market reception of its Renuvion product and its expansion into China through a partnership with GlamMoon Medical Technology, aiming to capitalize on a growing aesthetic market influenced by the increasing use of GLP-1 drugs.

Apyx Medical Financial Statement Overview

Summary
Apyx Medical faces substantial financial challenges across all verticals. The income statement shows declining revenue and persistent losses. The balance sheet reflects improved leverage but continued negative returns. Cash flow metrics indicate liquidity issues, with negative cash flows and growth rates. Overall, the company needs to address its profitability and cash flow concerns to improve its financial health.
Income Statement
35
Negative
Apyx Medical's income statement reveals significant challenges. The company has experienced declining revenue growth, with a negative growth rate in the TTM period. Profitability metrics such as net profit margin and EBIT margin are negative, indicating ongoing losses. Although the gross profit margin remains relatively stable, the overall financial health is concerning due to persistent negative earnings.
Balance Sheet
40
Negative
The balance sheet shows a mixed picture. The debt-to-equity ratio has improved in the TTM period compared to the previous year, suggesting better leverage management. However, the return on equity remains negative, reflecting continued losses. The equity ratio indicates a moderate level of equity financing, but the company's financial stability is undermined by ongoing losses.
Cash Flow
30
Negative
Cash flow analysis highlights significant issues. The company has negative operating and free cash flows, with a declining free cash flow growth rate. The operating cash flow to net income ratio is negative, indicating cash flow challenges. Despite a positive free cash flow to net income ratio, the overall cash flow position is weak, raising concerns about liquidity.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue46.51M48.10M52.35M44.51M48.52M27.71M
Gross Profit28.67M29.36M33.76M29.13M33.60M17.50M
EBITDA-11.49M-16.80M-18.11M-22.01M-13.91M-18.48M
Net Income-17.26M-23.46M-18.71M-23.28M-15.20M-11.91M
Balance Sheet
Total Assets58.19M64.84M79.24M51.77M68.72M74.11M
Cash, Cash Equivalents and Short-Term Investments29.30M31.74M43.65M10.19M30.87M41.91M
Total Debt4.71M38.76M38.50M796.00K305.00K676.00K
Total Liabilities50.73M50.51M52.32M13.98M14.71M10.25M
Stockholders Equity7.25M14.21M26.70M37.58M53.70M63.72M
Cash Flow
Free Cash Flow-10.03M-18.77M-5.78M-21.29M-11.17M-16.65M
Operating Cash Flow-9.31M-18.05M-5.25M-20.28M-10.45M-16.07M
Investing Cash Flow-718.00K-722.00K6.73M-1.01M-723.00K-581.00K
Financing Cash Flow6.80M6.75M32.17M217.00K24.00K-73.00K

Apyx Medical Technical Analysis

Technical Analysis Sentiment
Positive
Last Price2.39
Price Trends
50DMA
2.08
Positive
100DMA
1.99
Positive
200DMA
1.65
Positive
Market Momentum
MACD
0.04
Negative
RSI
62.77
Neutral
STOCH
83.86
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For APYX, the sentiment is Positive. The current price of 2.39 is above the 20-day moving average (MA) of 2.12, above the 50-day MA of 2.08, and above the 200-day MA of 1.65, indicating a bullish trend. The MACD of 0.04 indicates Negative momentum. The RSI at 62.77 is Neutral, neither overbought nor oversold. The STOCH value of 83.86 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for APYX.

Apyx Medical Risk Analysis

Apyx Medical disclosed 28 risk factors in its most recent earnings report. Apyx Medical reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Apyx Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
58
Neutral
$18.63M-64.55%15.60%
58
Neutral
$37.99M-210.58%30.16%22.51%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
49
Neutral
$61.80M-676.41%16.34%34.86%
47
Neutral
$90.39M-156.90%-5.14%44.86%
39
Underperform
$42.02M-125.63%6.48%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
APYX
Apyx Medical
2.39
1.12
88.19%
NVNO
enVVeno Medical
0.97
-2.23
-69.69%
ECOR
Electrocore
5.01
-2.94
-36.98%
MODD
Modular Medical
0.68
-1.58
-69.91%
TELA
TELA Bio
1.56
-1.06
-40.46%
RBOT
Vicarious Surgical
7.06
1.06
17.67%

Apyx Medical Corporate Events

Executive/Board ChangesShareholder MeetingsBusiness Operations and Strategy
Apyx Medical Holds Annual Stockholders Meeting
Neutral
Aug 13, 2025

On August 7, 2025, Apyx Medical Corporation held its annual stockholders meeting where several key proposals were voted on. The stockholders elected five directors, ratified RSM US LLP as the independent accounting firm for 2025, approved executive compensation resolutions, and amended the company’s Certificate of Incorporation. These decisions are expected to influence the company’s governance and operational strategies moving forward.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 30, 2025